301-968-3501, ITI Media: Immunomic Therapeutics Inc - Company Profile and News ITI is also collaborating with academic centers and biotechnology companies to study the use of UNITE in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. 301-968-3501 mkemp@immunomix.com The company was founded in 2005 and is based in Lancaster, Pennsylvania. Immunic is a biopharmaceutical company that develops a pipeline of selective oral immunology therapies. Jan 30, 2015. HLB also secured an option to make further investment into the company in the months ahead. Amy Conrad All content is posted anonymously by employees working at Immunomic Therapeutics. November 30, 2021, 7:01 PM UTC. It is one of the few malignancies for which incidence approximates prevalence, as patients almost always . No.93, Zhongyang Rd., Xindian Dist., New Taipei City 231, Taiwan. 1K followers 500+ connections. Equal Opportunity: ITI is committed to creating a diverse environment and is proud to be an Equal Opportunity Employer. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. 2017 Apr 15;23(8):1898-1909. Immunomic Therapeutics - Products, Competitors, Financials, Employees The company's immunomodulation platform, LAMP-Vax, enables nucleic acid immunotherapy (DNA or RNA) to utilize the body's natural . Great people . At ITI, our success is based in great part on our ability to attract and retain the best, creative, talented, motivated and productive employees throughout our organization. ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein) -mediated nucleic acid-based immunotherapy today announced the appointment of Brian Stamper to Vice President, Cell Therapy Operations. Team - Immunomic Therapeutics Sampson and Mitchell in the development of a new approach to attack Glioblastoma Multiforme (GBM). Pay, Holidays and PTO appear to be very good. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. The company was founded in 2005 and is based in Lancaster, Pennsylvania. Immunomic Therapeutics Announces Presentation on Nucleic Acid-Based San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. Immunomic Therapeutics investigational UNITEplatform is founded in a combination of complementary technologies and capabilities: ITIs proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale. In addition to our pipeline, we are also developing through collaborations with academic centers and biotechnology companies the use of the UNITE platform in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. Immunomic Therapeutics investigational UNITE platform is founded in a combination of complementary technologies and capabilities: ITIs proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale. Companies. Immunomic Therapeutics Announces Presentation on Nucleic Immunomic Therapeutics Announces the Appointment of Frances Harrison as Senior Vice President, Regulatory Affairs, Northeastern US Biotechnology Female Founded Companies. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product.ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers. January 30, 2015 - Immunomic Therapeutics, Inc. ("Immunomic Therapeutics "), a company developing next generation vaccines based on the LAMP-vax platform, and Astellas Pharma Inc. ("Astellas") today announced they have entered into an exclusive license agreement for Japan to . Find More Contacts for ImmunoMet Therapeutics, Edit Lists Featuring This Company Section, Dr. Revati Shreeniwas Joins ImmunoMet Therapeutics as Chief Medical Officer, ImmunoMet Therapeutics Appoints Vincent ONeill Chief Medical Officer, Health Care Companies With Less Than $1M in Revenue (Top 10K), Pharmaceutical Companies With Fewer Than 1000 Employees (Top 10K), Southern US Companies With Less Than $50M in Revenue (Top 10K). immunomic therapeutics crunchbase We are pleased to welcome HLB as a significant shareholder of Immunomic Therapeutics and look forward to working with them within the framework of the HLB Bio family of companies. Glioblastoma Multiforme (GBM) - Immunomic Therapeutics Immunomic Therapeutics, Inc. | LinkedIn The Immunomic Therapeutics, Inc. team includes specialists in the areas of science, process development, engineering, production, marketing, finance, human resources, quality and regulatory, administrative support and more. The Phase 2 protocol will remain active, the existing Principal Investigators (PIs . Founders Sungwuk Kim. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal . ITI is using the UNITE platform to develop vaccines against various infectious diseases, SARS-CoV-2 (COVID-19) among them. Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product.ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers. The initial foray into immuno-oncology was undertaken when ITI decided to support the work of Drs. Immunomic Therapeutics Assumes Sponsorship of ATTAC II IND - Duke OTC ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI) a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today the close of a $61.3M financing led by HLB Co., LTD, a global pharmaceutical company focused on developing novel cancer drugs. 301-968-3501 I would also like to take the opportunity to sincerely thank Louise Peltier for her leadership over the last seven years and wish her well in her retirement., I am both honored and excited to be joining Immunomic Therapeutics at such a critical point in its growth cycle, said Ms. Harrison. Juniper Point The company is developing three small molecule products; its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of. Immunomic Therapeutics considers applicants for all positions without regard to race, color, creed, religion, ancestry, national origin, age, gender identity, sex, marital status, sexual orientation, physical or mental disability, use of a guide dog or service animal, military/veteran status, citizenship status, basis of genetic information, or any other group protected by law. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. Immunic Therapeutics - Crunchbase Company Profile & Funding Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. aanagnostou@immunomix.com People with disabilities who need a reasonable accommodation to apply or compete for employment with Immunomic Therapeutics may request such accommodation(s) by sending an e-mail to: careers@immunomix.com. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization. Active, Closed, Last funding round type (e.g. New Taipei Municipal Hsin Tien Senior High School - Wikipedia Additionally, our expanded capabilities allow us to work with our corporate partners to better understand and develop the manufacturing process and product testing assays. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. For more information, please visit www.immunomix.com. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. The therapy was developed using ITIs proprietary UNITE (UNiversal Intracellular Targeted Expression) platform. Rockville's Immunomic Therapeutics Inc. is on track to go public later this year, after Covid-19 threw a wrench in the vaccine maker's initial timeline. MiNA Therapeutics Limited Translation & Innovation Hub 84 Wood Lane London W12 0BZ United Kingdom. ITI-3000 is being tested in a Phase 1, open label, First in Human (FIH) study to evaluate the safety, tolerability, and immunogenicity of 4 mg of ITI-3000 in patients with Merkel polyomavirus-positive Merkel cell carcinoma (MCC). Hum Vaccin Immunother. Animal Health All. Immunomic Therapeutics Receives FDA Fast Track Designation for ITI-3000, a pDNA Vaccine, in Development for the Treatment of Merkel Cell Carcinoma November 08, 2022 08:30 AM Eastern Standard Time In addition, ITI and HLB intend to establish an Asian Brain Cancer Research Center in Seoul that will bring together the worlds leading experts and cutting-edge science to advance research in the GBM field and to deploy ITI-1000 to the Asian population. April 23, 2020 04:00 PM Eastern Daylight Time. ITIs investigational UNITE platform, or UNiversal Intracellular Targeted Expression, works by fusing pathogenic antigens with the Lysosomal Associated Membrane Protein, an endogenous protein in humans, for immune processing. The first ITI oncology clinical program was born as a result of this decision and each subsequent asset in the pipeline represents a natural transition from this original point of entry into oncology. We have significant capabilities in molecular biology, including nucleic acid vaccine design, immunology, and tumor mouse modeling. ICT has established a broad portfolio of CAR-T products to treat cancer patients. Hope versus experience in glioblastoma | Evaluate Immunomic Therapeutics Receives FDA Fast Track Designation for ITI-3000 The UNITE platform can result in a number of downstream effects: CD4+ memory, cytokine production, and a potent antibody response. Company Type For Profit. 28 Employees . The company is developing three small molecule products; its lead development program, IMU-838, a selective . Our Pipeline | Xilio Therapeutics Pancreatic cancer is the fourth-most-common cause of cancer-related mortality in the USA. Immunic Therapeutics Company Profile: Stock Performance & Earnings Immunomic Therapeutics Strengthens Leadership Team with Appointment of We provide a professional and challenging work environment . Description. Bard (Becton, Dickinson and Company). 2015 Mar 19;519(7543):366-9. The Company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease, and allergy. Glassdoor gives you an inside look at what it's like to work at Immunomic Therapeutics, including salaries, reviews, office photos, and more. Pipeline - Immunomic Therapeutics Individuals who thrive in our environment are team-oriented, self-motivated, creative, and persistent. Checkmate-548 was the most recent hope for Opdivo in glioblastoma following the failures, in 2017 and 2019 respectively, of Checkmate-143 in the second-line setting and Checkmate-498 in first-line. This is the Immunomic Therapeutics company profile. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Due to the volume of inquiries received, we regret that we cannot contact all applicants personally. Over 100 studies have been published on LAMP, ranging from those focused on the fundamental biology of lysosomal associated membrane protein to the immunobiology of novel vaccine candidates. Claim your Free Employer Profile. Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines for the treatment of allergy and other human health targets. ITI Company: IMU-935, a selective inverse agonist of the transcription factor RORt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barr syndrome. Our Company Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE ), which is designed to utilize the body's natural biochemistry to develop vaccines that generate broad immune responses Read More Our Focus ITI is . We believe that these early clinical studies may provide a proof of concept for UNITE in cancer, and if successful, set the stage for future studies, including combinations in this tumor type and others. 717-327-1822, ITI Media: Immunomic, Colmmune partner on cancer immunotherapy - ScienceBoard.net Those studies had enrolled all comers, and Bristol restricted Checkpoint-548's enrolment to patients carrying the MGMT methylation biomarker in . ITI-1000 GBM - Cell Therapy. ITI-1000 GBM - Cell Therapy. 2017 Jun 12:1-10. Their LAMP-Vax platform is thought to work by encoding the Lysosomal Associated Membrane Protein, an endogenous protein in . The majority of Merkel cell carcinomas (MCC), a rare but aggressive form of skin cancer, are associated with MCPyV infection, making LT an attractive target for this cancer vaccine. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. Our goal is to overcome the limitations of current immuno-oncology therapies by . Find all information and best deals of Chinatrust Executive House Hsin-Tien, New Taipei City on Trip.com! Brians specific and deep knowledge of cell therapy manufacturing and operations will be invaluable as we prepare for phase 3 testing of ITI-1000, our lead dendritic cell therapy for the treatment of glioblastoma multiforme (GBM).. ITI granted Japanese animal health company, ZENOAQ (Nippon Zenyaku Kogyo Co., Ltd, Koriyama, Japan) an exclusive license to develop and commercialize its investigational DNA vaccine for canine atopic dermatitis and other companion animal allergies. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. Phone Number +119196161923. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. This approach could put UNITE at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. UNITE is a groundbreaking approach to vaccine development that has been applied to create vaccine candidates for rabies, yellow fever, dengue fever, hepatitis C and SARS, a relative to the SARS-CoV-2 coronavirus.
Charl Schwartzel Witb 2021, Articles I